瑞士的降脂疗法:利用和成本的时间趋势,2015-2023年
Simon Wolf1, Jonathan Zufferey2, Nils Kucher3
1Department of Vascular Medicine, University Hospital Zurich, University of Zurich, Raemistasse 100, Zurich, 8091, Switzerland. simon.wolf@usz.ch.
Lipids in health and disease
|November 18, 2025
概括
瑞士的降脂疗法使用量从2015年到2023年增加,主要是由于新的药物组合. 虽然PCSK9抑制剂很少使用,但它们显著增加了整体治疗成本.
科学领域:
- 心脏病学 心脏病学
- 药物经济学 药物经济学
- 公共卫生 公共卫生
背景情况:
- 瑞士的降脂疗法 (LLT) 国家利用趋势此前曾在2013-2019年进行过研究.
- 2019年,欧洲心脏病学会 (ESC) 的新指导方针和新的降脂药物出现.
- 本研究评估了2015年至2023年的瑞士LLT利用率和成本.
研究的目的:
- 评估瑞士使用降脂疗法 (LLT) 的国家趋势.
- 从2015年到2023年分析LLT的经济影响和成本演变.
- 评估更新的ESC指南和新的药物类别对LLT处方模式的影响.
主要方法:
- 全国对瑞士行政索赔数据的分析 (瑞士关税池).
- 对每1000名居民的定义每日剂量 (DDD) 的推断,用于LLT的使用.
- 在瑞士法郎和欧元中标准化LLT成本.
主要成果:
- 每千人口中LLT的使用率从95.7增加到113.1DDD (2015-2023年).
- 总体而言,LLT成本从2.18亿瑞士法郎上升到2.75亿瑞士法郎.
- 立方体使用转向组合药物;PCSK9抑制剂,虽然使用率低,但导致成本增加 (2023年市场份额为22.1%).
结论:
- 瑞士的LLT使用量正在增加,这是由于新的药物组合推动的.
- 尽管使用率很低,但PCSK9抑制剂对LLT成本的上升有显著的贡献.
- 变化中的失脂症管理环境需要持续的药物经济评估.
相关概念视频
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
1.3K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.3K
01:26Atherosclerosis III: Management
301
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
301
01:29Therapeutic Drug Monitoring: Affecting Factors
183
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
183
01:19Antiasthma Drugs: Leukotriene Modifiers
1.7K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
1.7K
01:14Time Course of Drug Effect
2.6K
The progression of a drug's impact can be analyzed by examining both the concentration-time course and the effect-time course. The concentration-time course is determined by the drug's half-life and is influenced by factors such as its pharmacokinetics, including absorption, distribution, metabolism, and elimination. The effect of the drug is often related to its concentration in the plasma and is calculated using the maximum drug effect and the plasma concentration that generates 50...
2.6K
01:20Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
162
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
162